Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 8/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21190838 | 0.89 | BRD4 (0.44) | BRD4SLC6A4SLC6A2SLC6A3PGR | |
| SCHEMBL21190837 | 0.88 | PGR (0.51) | BRD4SLC6A4SLC6A2SLC6A3PGR | |
| SCHEMBL16650216 | 0.88 | BRD4 (0.50) | BRD4 | |
| SCHEMBL21190941 | 0.82 | BRD4 (0.46) | BRD4SLC6A4SLC6A2SLC6A3NR3C2 | |
| SCHEMBL14880907 | 0.82 | CA12 (0.43) | BRD4 | |
| SCHEMBL21190841 | 0.81 | BRD4 (0.48) | BRD4PGR | |
| SCHEMBL21190853 | 0.81 | BRD4 (0.45) | BRD4SLC6A4 | |
| SCHEMBL21190884 | 0.80 | BRD4 (0.44) | BRD4SLC6A4SLC6A2SLC6A3PLA2G7 | |
| SCHEMBL29814304 | 0.80 | BRD4 (0.44) | BRD4SLC6A4SLC6A2SLC6A3PLA2G7 | |
| SCHEMBL21191095 | 0.80 | CA1 (0.37) | BRD4SLC6A4SLC6A2SLC6A3NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2020-11-12 | — | — | US | disclosed |
| WO-2019141131-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | 中国科学院上海药物研究所 | 2019-07-25 | — | — | WO | disclosed |
| US-9359548-B2 | Organic electroluminescent device | UDC IRELAND LIMITED (IE) | 2016-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200354371-A1 | BROMODOMAIN INHIBITOR COMPOUND AND USE THEREOF | BRD4, BRD1, BRD3 | BRD4 1/4885SLC6A4 3879/4885SLC6A2 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.